Good MorningEquity markets wobbled again on Wednesday as hotter than expected inflation data capped gains driven by better-than-expected earnings. Reports from the big banks reveal ongoing improvement in the consumer but that news was overshadowed by inflation fears. The producer price index, a leading indicator of consumer inflation, rose 1.0% from the previous month in an acceleration that drove year-over-year inflation to 7.3%.
The news was compounded by testimony from Fed Chief Jerome Powell who says that inflation has accelerated unexpectedly and that high inflation could linger for months. Even so, the FED Chief says there's no expectation for raising interest rates anytime soon. The next big test for the market will come over the next two days with the release of several important economic data points Featured: Take your IRA to the next level by investing in gold (Gold Allied Trust) 
|
Stocks | | | While DoorDash (NYSE: DASH) and Airbnb (NASDAQ: ABNB) are among the recent IPOs with the most buzz, they’re actually being trounced in the price-performance department by slightly older IPOs OneMain Holdings (NYSE: OMF), Customers Bancorp (NYSE: CUBI) and InMode (NASDAQ: INMD). All three sport strong one-year and year-to-date gains, as well as solid fundamentals. Read the Full Story |
|
From Our PartnersThere’s a little-known technique to buy Bitcoin below fair market value right now. If you’ve been on the fence, now may be the perfect opportunity. Works with: TD Ameritrade®, Schwab®, Fidelity®, E*Trade®, Interactive Brokers®, Tradestation®, Merrill®, and many more! Even in an IRA or 401K.
Hurry, this “Discount Window” is closing FAST! | | Discover how >> |
|
Politics | | | China’s economic growth slowed to a still-strong 7.9% over a year earlier in the three months ending in June as a rebound from the coronavirus leveled off.
As expected, the growth reported Thursday fell from the previous quarter’s explosive 18.3%, which was magnified by comparison wit... Read the Full Story |
|
Politics | | | China’s government rejected U.S. accusations of forced labor in Xinjiang and accused Washington on Thursday of hurting global trade after lawmakers endorsed import curbs and American companies were warned they face legal risks if they do business with the region.
The measures add to r... Read the Full Story |
|
From Our PartnersElon Musk and Tesla still have one BIG PROBLEM that could derail the whole electric vehicle market. No, it’s not lithium. It’s another resource that’s even more critical for electric vehicles. And right now there’s one tiny $4 stock that is uniquely set up to benefit from this booming demand. | | | | Click here to see why |
|
Markets | | | Asian shares were mixed Thursday, taking their cues from a wobbly day of trading on Wall Street.
China reported its economy expanded at a 7.9% annual rate in the last quarter, down from 18.3% in January-March in a leveling off of its relatively early recovery from th... Read the Full Story |
|
Markets | | | Global shares were mostly lower on Thursday after China reported its economic growth slowed in the April-June quarter to a still robust 7.9%.
France's CAC 40 slipped 0.2% in early trading to 6,547.07. Germany's DAX edged down 0.5% to 15,710.47, while Britain's FTSE 100 gained less th... Read the Full Story |
|
From Our PartnersExpand your portfolio by adding Real Estate Stocks and REITs that have outperformed the S&P 500 since the 1970s. Learn about these overlooked stocks and add high performance and stability to your portfolio. | | Download the eBook FREE |
|
Tech | | | Toyota plans to hire more people and invest heavily in its subsidiary Woven Planet to work on mobility technology so the Japanese automaker stays competitive amid the global shift to using artificial intelligence and robotics in everyday driving.
“Toyota’s traditional strength in har... Read the Full Story |
|
Markets | | | It might be a good idea to increase your exposure to these businesses, as they should see a nice uptick in their earnings as a result. That’s why we’ve prepared the following list of 3 stocks to buy as consumer borrowing rebounds. Read the Full Story |
|
Stocks | | | Wells Fargo (NYSE: WFC) is faced with a headwind that has emerged for the entire banking sector. The massive amounts of stimulus pumped into the economy are improving general conditions including consumer health and that is cutting into net interest income Read the Full Story |
|
Markets | | | Organigram (NASDAQ: OGI), and the entire Canadian cannabis market, have been struggling in the wake of the COVID-19 pandemic. It's not that demand has evaporated so much as it is that stores have been closed and people can't get the product. Read the Full Story |
|
Markets | | | Did you neglect taking career assessments during high school or college? You may be sacrificing major retirement savings if you're not in the right career. Knowing yourself can help you earn and save more, especially if you're in a career that really fits your personality and needs. Read the Full Story |
|
The Early Bird Stock Of The Day Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. | | View Today's Stock Pick |
|
